DMI and 4-OI have been researched to have promising effects on psoriasis, rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus due to their ability to suppress IL-17 signaling and reduce proinflammatory cytokine production (3, 6). Here, IL17A is linked to multiple sclerosis.